Literature DB >> 26098015

Graphical representation of clinical outcomes for patients with myelodysplastic syndromes.

David P Steensma1.   

Abstract

The causes of death in patients with myelodysplastic syndromes (MDS) are diverse: infections, hemorrhage, complications of chronic anemia and repeated blood transfusions, and complications of progression to acute myeloid leukemia. Since most patients with MDS are diagnosed late in life, some individuals with MDS will succumb to an unrelated condition, such as one of the disorders that are common in geriatric populations. Currently, only a small proportion of patients with MDS - less than 5% - undergo allogeneic stem cell transplantation, a procedure that offers the only possibility of cure. This brief review summarizes outcomes for patients diagnosed with MDS using a pictographical format that illustrates both the challenges patients face and the pressing need for development of novel therapies, as well as highlighting the potential for increased use of allogeneic stem cell transplant. This informational graphic may be useful for teaching or in counseling certain patients.

Entities:  

Keywords:  Patient outcomes; causes of death; infographic; myelodysplastic syndromes; stem cell transplantation

Mesh:

Year:  2015        PMID: 26098015     DOI: 10.3109/10428194.2015.1061191

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

1.  Risk and timing of cardiovascular death among patients with myelodysplastic syndromes.

Authors:  Andrew M Brunner; Traci M Blonquist; Gabriela S Hobbs; Philip C Amrein; Donna S Neuberg; David P Steensma; Gregory A Abel; Amir T Fathi
Journal:  Blood Adv       Date:  2017-10-18

Review 2.  Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity.

Authors:  Andrew M Brunner; David P Steensma
Journal:  Hematol Oncol Clin North Am       Date:  2019-12-11       Impact factor: 3.722

Review 3.  Infographics: Healthcare Communication for the Digital Age.

Authors:  A D McCrorie; C Donnelly; K J McGlade
Journal:  Ulster Med J       Date:  2016-05

Review 4.  DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders.

Authors:  Hanae Sato; Justin C Wheat; Ulrich Steidl; Keisuke Ito
Journal:  Front Oncol       Date:  2016-08-22       Impact factor: 6.244

Review 5.  Myelodysplastic syndromes current treatment algorithm 2018.

Authors:  David P Steensma
Journal:  Blood Cancer J       Date:  2018-05-24       Impact factor: 11.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.